Indeed, with daratumumab for example, the release of CD38 from MM cells by microvesicles and the transfer of CD38–daratumumab complexes from myeloma cells to monocytes and granulocytes have been reported [59,60]. This evidence concerns the gene CD38 and plasma cell myeloma.